[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer]

Rev Pneumol Clin. 2016 Oct;72(5):300-304. doi: 10.1016/j.pneumo.2016.05.004. Epub 2016 Aug 22.
[Article in French]

Abstract

Introduction: Pembrolizumab, a humanized monoclonal antibody IgG4 anti-PD-1, having offered promising results in patients suffering from non-small cell lung cancer metastatic and heavily pretreated.

Observation: We report here the case of an unexpected good response after pembrolizumab failure obtained with paclitaxel in a 68-year-old patient with stage IV lung adenocarcinoma. Moreover, the response duration with paclitaxel was more than fourteen months.

Conclusion: Our case suggests a mutual potentiation of chemotherapy and immunotherapy, and raises the issue of the treatment sequence to favor.

Keywords: Advanced non-small-cell lung cancer; Cancer bronchique non à petites cellules avancé; Checkpoint inhibitors; Immunotherapy; Immunothérapie; Inhibiteurs des points de contrôle immunologiques; Pembrolizumab.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunotherapy*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Paclitaxel / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab
  • Paclitaxel